B3 is a monoclonal antibody that reacts with a carbohydrate epitope present on a variety of proteins located on the surface of many cancer cells and a limited number of normal tissues. We evaluated the cytotoxic activity of immunotoxins composed of monoclonal antibody B3 coupled to native Pseudomonas exotoxin (PE) or two recombinant forms of Pseudomonas exotoxin, PEArW or LysPE40, a form of PE with a deletion of the cell binding domain. All three conjugates were cytotoxic to human cell lines expressing the B3 antigen on their surface. The survival of each of the three immunotoxins in the circulation of mice was determined after administering the immunotoxin i.v. The half-life in blood of B3-PE and B3-PEArO7 was 20 hr, whereas the half-life of B3-LysPE40 was 4
Immunotoxins are potent cell killing agents that are emerging as chemotherapeutic agents for the treatment of cancer, acquired immune deficiency syndrome (AIDS), and some immunological disorders (1) (2) (3) (4) (5) . We have been developing an alternate approach to conventional cancer chemotherapy using immunotoxins made from Pseudomonas exotoxin (PE) or genetically modified forms of PE coupled to antibodies reactive with antigens present on the surface of solid tumors. Initially, we showed that immunotoxins containing antibodies to the human transferrin receptor were very effective cell-killing agents in vitro and in vivo (6) . However, these agents have limited clinical utility, because they react with many vital normal human tissues. We isolated a monoclonal antibody reactive with many ovarian cancers and coupled this antibody (OVB3) to PE. This immunotoxin, OVB3-PE, was shown to kill human ovarian cancer cells in culture and to prolong the life of nude mice bearing human ovarian tumors (7) . However, this agent was poorly tolerated in a phase I trial in women because ofthe reactivity of OVB3 with some cells in normal human cerebellum (unpublished data).
Therefore, it was necessary to obtain a more tumor-specific antibody with no cross reactivity to vital human tissues.
We have isolated a murine monoclonal antibody termed B3, that shows strong reactivity with many mucin-producing tumors of the ovary, stomach, and colon, as well as strong reactivity with nonmucinous carcinomas of the colon and stomach (I.P., L.H.P., E. T. Lovelace, M. G. Gallo Lysine-57 (domain I) was shown to be involved in the cellular binding of PE (11) , and when mutated to arginine, its cytotoxic activity on mouse L929 cells fell about 5-fold (unpublished data). LysPE40 is a 40-kDa recombinant form of PE that lacks all of domain I and contains an extra lysine residue near its amino end to facilitate coupling to antibodies (6) .
The current report describes the characteristics and activity of three immunotoxins in which B3 was coupled to native PE to make B3-PE, to PEAm7 to make B3-PEAxW7, or to LysPE40 to make B3-LysPE40.
MATERIALS AND METHODS
Monodonal Antibody B3. The isolation and characterization of B3 will be described in detail elsewhere. Briefly, BALB/c mice were tolerized with normal human kidney membranes and immunized with trypsin-treated MCF-7 cells. Spleens from immunized mice were removed and the suspended cells were fused with AG8 mouse myeloma cells. The antibodies produced by the resulting clones were screened 2 weeks later using rhodamine indirect immunofluorescence on living MCF-7 cells. Screening was carried out using a ScreenFast (Life Technologies, Gaithersburg, MD) large-scale screening chamber (12) . Selected clones were secondarily screened using peroxidase immunohistochemistry on cryostat sections of human tumors and norAbbreviation: PE, Pseudomonas exotoxin. *To whom reprint requests should be addressed.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. PE, PEA'O', and LysPE40. PE purified from the culture medium of Pseudomonas aeruginosa was purchased from Swiss Serum (Berne, Switzerland). PEArg7 was prepared from the periplasm of E. coli as described for other PE constructs using plasmid pJY557R (Y. Jinno, V. Chaudhary, and I.P., unpublished data). LysPE40 was prepared from the medium as described (6) . Construction of Immunocohjugates. PE, PEArg57, or LysPE40 at 5-10 mg/ml in 0.2 M sodium phosphate (pH 7.0) containing 1 mM EDTA was mixed with a 3-fold molar excess of succinimidyl-4-(N-maleimidomethyl)cyclohexane-lcarboxylate and incubated at room temperature for 30 min. Protein was separated from the unreacted cross-linker on a PD10 column. Monoclonal antibody (B3 or MOPC-21) at 5-10 mg/ml was mixed with a 3-fold molar excess of 2-iminothiolane hydrochloride in 0.2 M sodium phosphate (pH 8.0) containing 1 mM EDTA and incubated at 37°C for 1 hr. The derivatized antibody was separated from the reactants on a PD10 column. Derivatized antibody and PE, PEW', or LysPE40 were mixed and incubated at room temperature for 16-20 hr. Immunotoxin was then purified by successive chromatography on MonoQ and TSK 250 columns (13) . SDS/PAGE was done as described (13 cific, because they are completely eliminated by the addition of excess B3 (25 Ag/ml).
The potent cytotoxic activity of the immunotoxins containing B3 suggested that these agents might be effective against tumors bearing the B3 antigen. To determine the blood levels that could be achieved in these mice and the duration that the immunotoxin would be present in the blood, 1 Lg of B3-PE, 1 Ag of B3-PEAr 7, or 20 ,ug of B3-LysPE4O were administered to groups of mice. The immunotoxins were given intravenously and serum samples were collected beginning 2 min after the i.v. injection. The data in Fig. 3 show the blood levels of the three immunotoxins. B3-PE and B3-PEArg57 decayed slowly with an apparent half-life of about 20 hr. B3-LysPE40 decayed more quickly with an apparent half-life of about 4 hr.
Because the immunotoxins were present at substantial concentrations for many hours, it seemed possible that they might exert an anti-tumor effect. Therefore, the anti-tumor activity of the immunotoxin was assessed in nude mice bearing A431 human epidermoid cancer cells. To do this, 3 x 106 cells were injected subcutaneously on day 0. Treatment was started on day 4 with either PBS or immunotoxin dissolved in PBS. On day 4, the tumors measured about 5 x 5 mm and were about 50 mm3 in size. As shown in Fig. 4 , in animals that were given three doses of 0.75 Mg of B3-PE or B3-PEAI57 on days 4, 6 , and 8, the tumors completely disappeared and remained undetectable for 3 months. The two groups, control and treated, were compared at each time point using the Wilcoxon rank test. Beginning on day 12 there was a significant anti-tumor effect evident with both B3-PE and B3-PEArg57 (P2 < 0.005). In the animals treated on days 7, 9, and 11, the tumors stopped growing, regressed somewhat, and then resumed their growth. In animals treated on days 7, 9, 11, 13, and 15, the tumors regressed substantially leaving a hemorrhagic mass with a rim of living cancer cells. The mass then remained at about the same size for 24 days (P2 = 0.009). To determine the anti-tumor activity of B3-LysPE40, groups of animals bearing A431 tumors were treated every other day i.p. with the immunoconjugate at dose levels of2.5, 10, and 20 ug. Treatment was initiated on day 4. As shown in Fig. 6 , at the dose level of 20 ,g, complete remission of the tumor was observed that lasted for at least 3 months (P2 < 0.0001). With 10 Mg and 2.5 ug, only partial remissions were observed.
DISCUSSION
In this study, we have shown that immunotoxins made with B3, a monoclonal antibody that reacts with many human carcinomas, kill cell lines reacting with the antibody and cause regression of a human epidermoid carcinoma. In addition, we have found that B3-PE causes regression of the MCF-7 breast carcinoma (unpublished data). B3 was coupled to several forms of PE. The toxicity in animals of immunotoxins made with native PE is mainly due to the binding of domain I of PE to liver cells (9) . To minimize the toxic effect of PE due to its nonspecific binding, we made immunoconjugates with two recombinant forms of PE, PEA`97 and LysPE40. PEAr57 is approximately 5-fold less toxic to murine L929 cells than native PE; it is also less toxic to mice than native PE. The anti-tumor activities ofthe immunoconjugates B3-PE and B3-PEAr57 in vitro and in mice are very similar (Fig. 1) . However, the LD50 values of the two conjugates in mice showed only small differences. The single-dose LD50 is 2.5 ,ug for B3-PE and 3.5 1Lg for B3-PEA 57. Although not significant, these findings suggest that this recombinant form of PE may have a small advantage over native PE for use in immunoconjugates due to its slightly lower toxicity. In contrast, LysPE40 appears to be a superior molecule for conjugation with monoclonal antibodies. B3-LysPE40 has no detectable cytotoxicity against cultured cells to which the antibody does not bind. Furthermore, 20 ,g of B3-LysPE40 has a remarkable antitumor activity when injected three to five times. The single-dose LD50 of the B3-LysPE40 is about 200 ug.
When administered i.v. in mice at a dose of 1 ,tg, B3-PE and B3AWr7 have half-lives of 20 hr; this is to be compared with B3-LysPE40, which has a half-life of only 4 hr. The absence of domain I of PE not only has an effect on the binding of PE to cells (9) but also shortens its half-life in mice. The biochemical basis ofthis difference in half-life remains to be determined.
All three conjugates produced complete regression of actively growing solid tumors using doses that were nontoxic to animals. When the tumors were allowed to grow to a larger size, four doses of the immunotoxin decreased the tumor size, the mass became hemorrhagic, and the overlying skin became necrotic probably due to infiltration of the tumor into the skin. Because of this skin necrosis leading to potential infection in these immunodeficient animals, further doses could not be administered to determine if these tumors could also be completely eliminated.
In summary, B3 is a monoclonal antibody that shows strong reactivity with many solid tumors, including mucinous and nonmucinous adenocarcinomas. Its limited reactivity with normal human tissues may make it useful for targeted therapy in humans. Because B3 reacts with monkey tissues in a manner similar to that of human tissues, it should be possible to determine if an immunotoxin composed of B3 and one or more forms of PE has properties that indicate it should be evaluated in patients with cancer.
